Literature DB >> 16547138

CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis.

Jian Hong1, Ying C Q Zang, Hong Nie, Jingwu Z Zhang.   

Abstract

Immunization with irradiated autologous T cells (T cell vaccination) is shown to induce regulatory T cell responses that are poorly understood. In this study, CD4(+) regulatory T cell lines were generated from patients with multiple sclerosis that received immunization with irradiated autologous myelin basic protein-reactive T cells. The resulting CD4(+) regulatory T cell lines had marked inhibition on autologous myelin basic protein-reactive T cells and displayed two distinctive patterns distinguishable by the expression of transcription factor Foxp3 and cytokine profile. The majority of the T cell lines had high Foxp3 expression and secreted both IFN-gamma and IL-10 as compared with the other pattern characteristic of low Foxp3 expression and predominant production of IL-10 but not IFN-gamma. CD4(+) regulatory T cell lines of both patterns expressed CD25 and reacted with activated autologous T cells but not resting T cells, irrespective of antigen specificity of the target T cells. It was evident that they recognized preferentially a synthetic peptide corresponding to residues 61-73 of the IL-2 receptor alpha chain. T cell vaccination correlated with increased Foxp3 expression and T cell reactivity to peptide 61-73. The findings have important implications in the understanding of the role of CD4(+) regulatory T cell response induced by T cell vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547138      PMCID: PMC1458788          DOI: 10.1073/pnas.0508784103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  T-cell vaccination: from basics to the clinic.

Authors:  V Kumar; E Sercarz; J Zhang; I Cohen
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

Review 2.  T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis.

Authors:  Jingwu Zhang
Journal:  Expert Rev Vaccines       Date:  2002-10       Impact factor: 5.217

Review 3.  Tregs in T cell vaccination: exploring the regulation of regulation.

Authors:  Irun R Cohen; Francisco J Quintana; Avishai Mimran
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis.

Authors:  Y C Zang; J Hong; M V Tejada-Simon; S Li; V M Rivera; J M Killian; J Z Zhang
Journal:  Eur J Immunol       Date:  2000-03       Impact factor: 5.532

5.  T cell vaccination in secondary progressive multiple sclerosis.

Authors:  J Correale; B Lund; M McMillan; D Y Ko; K McCarthy; L P Weiner
Journal:  J Neuroimmunol       Date:  2000-07-24       Impact factor: 3.478

6.  T cell vaccination in multiple sclerosis: results of a preliminary study.

Authors:  Jingwu Z Zhang; Victor M Rivera; Maria V Tejada-Simon; Deye Yang; Jian Hong; Sufanfg Li; Hani Haykal; James Killian; Ying C Q Zang
Journal:  J Neurol       Date:  2002-02       Impact factor: 4.849

7.  Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.

Authors:  Roland Schroers; Xue F Huang; Juergen Hammer; Jingwu Zhang; Si-Yi Chen
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

8.  Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells.

Authors:  Ying C Q Zang; Jian Hong; Victor M Rivera; James Killian; Jingwu Z Zhang
Journal:  Int Immunol       Date:  2003-09       Impact factor: 4.823

9.  DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide.

Authors:  Francisco J Quintana; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

10.  T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Authors:  A Van der Aa; N Hellings; R Medaer; G Gelin; Y Palmers; J Raus; P Stinissen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

View more
  11 in total

1.  Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses.

Authors:  Siguo Hao; Yongqing Liu; Jinying Yuan; Xueshu Zhang; Tianpei He; Xiaochu Wu; Yangdou Wei; Deming Sun; Jim Xiang
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 2.  [Cellular therapy in autoimmune disease].

Authors:  K Thümmler; A Ramming; H Schulze-Koops; A Skapenko
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

3.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 4.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Authors:  Arthur A Vandenbark; Rivka Abulafia-Lapid
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

6.  Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.

Authors:  Kerrington R Molhoek; Chantel C McSkimming; Walter C Olson; David L Brautigan; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2008-10-08       Impact factor: 6.968

7.  Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

Authors:  Arthur A Vandenbark; Nicole E Culbertson; Richard M Bartholomew; Jianya Huan; Marci Agotsch; Dorian LaTocha; Vijayshree Yadav; Michele Mass; Ruth Whitham; Jesus Lovera; June Milano; Georgia Theofan; Yuan K Chou; Halina Offner; Dennis N Bourdette
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

8.  T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Authors:  Dimitrios Karussis; Hagai Shor; Julia Yachnin; Naama Lanxner; Merav Amiel; Keren Baruch; Yael Keren-Zur; Ofra Haviv; Massimo Filippi; Panayiota Petrou; Shalom Hajag; Urania Vourka-Karussis; Adi Vaknin-Dembinsky; Salim Khoury; Oded Abramsky; Henri Atlan; Irun R Cohen; Rivka Abulafia-Lapid
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

Review 9.  Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging.

Authors:  Brandon Coder; Weikan Wang; Liefeng Wang; Zhongdao Wu; Qichuan Zhuge; Dong-Ming Su
Journal:  Oncotarget       Date:  2017-01-24

10.  HSP60 as a target of anti-ergotypic regulatory T cells.

Authors:  Francisco J Quintana; Avishai Mimran; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  PLoS One       Date:  2008-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.